{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:46:45Z","timestamp":1786718805982,"version":"build-2736575974"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Taiwan J Ophthalmol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/tjo.tjo_39_17","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T01:34:17Z","timestamp":1503538457000},"page":"67","source":"Crossref","is-referenced-by-count":11,"title":["Update on ocular myasthenia gravis in Taiwan"],"prefix":"10.4103","volume":"8","author":[{"given":"Lin-Chung","family":"Woung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieh-Ren","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2211-5056.213655-1","first-page":"537","volume-title":"Ocular myasthenia gravis","author":"Vaphiades","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"key-10.4103\/2211-5056.213655-2","first-page":"928","volume-title":"Increasing incidence of late-onset anti-AChR antibody- seropositive myasthenia gravis","author":"Somnier","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-3","first-page":"572","volume-title":"Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan","author":"Matsuda","year":"2005","journal-title":"Intern Med"},{"key":"key-10.4103\/2211-5056.213655-4","first-page":"1526","volume-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","author":"Pakzad","year":"2011","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-5","first-page":"26","volume-title":"Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles","author":"Serra","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/2211-5056.213655-6","first-page":"516","volume-title":", Aquino AV, Penn AS, Lovelace RE, Rowland LP.Prognosis of ocular myasthenia","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2211-5056.213655-7","first-page":"141","volume-title":"Lifetime course of myasthenia gravis","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-8","first-page":"43","volume-title":"An update on laboratory diagnosis in myasthenia gravis","author":"Oger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"key-10.4103\/2211-5056.213655-9","first-page":"66","volume-title":"Nationwide population-based epidemiological study of myasthenia gravis in Taiwan","author":"Lai","year":"2010","journal-title":"Neuroepidemiology"},{"key":"key-10.4103\/2211-5056.213655-10","doi-asserted-by":"crossref","unstructured":"Wang HS. Myasthenia gravis: Generalized vs. ocular, and children vs. adults. Arch Neurol 2003;60:1491.","DOI":"10.1001\/archneur.60.10.1491-a"},{"key":"key-10.4103\/2211-5056.213655-11","first-page":"171","volume-title":"The incidence of myasthenia gravis: A systematic literature review","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"key":"key-10.4103\/2211-5056.213655-12","first-page":"763","volume-title":"Epidemiology of myasthenia gravis in Austria: Rising prevalence in an ageing society","author":"Cetin","year":"2012","journal-title":"Wien Klin Wochenschr"},{"key":"key-10.4103\/2211-5056.213655-13","first-page":"340","volume-title":"Incidence and prevalence of myasthenia gravis in Korea: A population-based study using the National Health Insurance Claims Database","author":"Park","year":"2016","journal-title":"J Clin Neurol"},{"key":"key-10.4103\/2211-5056.213655-14","first-page":"221","volume-title":"Geographical distribution of myasthenia gravis in Northern Europe \u2013 Results from a population-based study from two countries","author":"Boldingh","year":"2015","journal-title":"Neuroepidemiology"},{"key":"key-10.4103\/2211-5056.213655-15","first-page":"41","volume-title":"Epidemiology of myasthenia gravis in Ontario, Canada","author":"Breiner","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"key-10.4103\/2211-5056.213655-16","first-page":"413","volume-title":"Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases","author":"Santos","year":"2016","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-17","first-page":"690","volume-title":"Update on myasthenia gravis","author":"Thanvi","year":"2004","journal-title":"Postgrad Med J"},{"key":"key-10.4103\/2211-5056.213655-18","first-page":"245","volume-title":"Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: A population-based cohort study","author":"Yeh","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"key-10.4103\/2211-5056.213655-19","first-page":"132","volume-title":"Risk of diabetes mellitus among patients with myasthenia gravis","author":"Yeh","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"key-10.4103\/2211-5056.213655-20","first-page":"1075","volume-title":"Increased risk of osteoporosis in patients with myasthenia gravis: A population-based cohort study","author":"Yeh","year":"2014","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-21","first-page":"e835","volume-title":"Higher risk of myasthenia gravis in patients with thyroid and allergic diseases: A national population-based study","author":"Yeh","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/2211-5056.213655-22","first-page":"325","volume-title":"Ocular Manifestations of Myasthenia Gravis","author":"Woung","year":"1985","journal-title":"Acta Soc Ophthalmologicae Sinicae"},{"key":"key-10.4103\/2211-5056.213655-23","first-page":"1","volume-title":"Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis","author":"Roh","year":"2011","journal-title":"Korean J Ophthalmol"},{"key":"key-10.4103\/2211-5056.213655-24","first-page":"1282","volume-title":"An ice test for the diagnosis of myasthenia gravis","author":"Golnik","year":"1999","journal-title":"Ophthalmology"},{"key":"key-10.4103\/2211-5056.213655-25","first-page":"288","volume-title":"The sleep test for myasthenia gravis.A safe alternative to Tensilon","author":"Odel","year":"1991","journal-title":"J Clin Neuroophthalmol"},{"key":"key-10.4103\/2211-5056.213655-26","first-page":"203","volume-title":"Repetitive nerve stimulation of facial and hypothenar muscles: Relative sensitivity in different myasthenia gravis subgroups","author":"Zambelis","year":"2011","journal-title":"Eur Neurol"},{"key":"key-10.4103\/2211-5056.213655-27","first-page":"61","volume-title":"Single-fiber EMG with a concentric needle electrode: Validation in myasthenia gravis","author":"Sarrigiannis","year":"2006","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-28","first-page":"1054","volume-title":"Antibody to acetylcholine receptor in myasthenia gravis.Prevalence, clinical correlates, and diagnostic value","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-29","first-page":"994","volume-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"key-10.4103\/2211-5056.213655-30","first-page":"496","volume-title":"Clinical implementation of anti-acetylcholine receptor antibodies","author":"Somnier","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/2211-5056.213655-31","first-page":"1682","volume-title":"AChR phosphorylation and indirect inhibition of AChR function in seronegative MG","author":"Plested","year":"2002","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-32","first-page":"2304","volume-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"key-10.4103\/2211-5056.213655-33","first-page":"2131","volume-title":"Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese","author":"Yeh","year":"2004","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-34","first-page":"572","volume-title":"Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan","author":"Huang","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"key-10.4103\/2211-5056.213655-35","first-page":"1002","volume-title":"Anti-MuSK myasthenia gravis presenting with purely ocular findings","author":"Caress","year":"2005","journal-title":"Arch Neurol"},{"key":"key-10.4103\/2211-5056.213655-36","first-page":"659","volume-title":"MuSK-antibody positive pure ocular myasthenia gravis","author":"Hanisch","year":"2006","journal-title":"J Neurol"},{"key":"key-10.4103\/2211-5056.213655-37","first-page":"564","volume-title":"Anti-MuSK antibodies in a case of ocular myasthenia gravis","author":"Bennett","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/2211-5056.213655-38","first-page":"445","volume-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"key-10.4103\/2211-5056.213655-39","first-page":"139","volume-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"key-10.4103\/2211-5056.213655-40","first-page":"62","volume-title":"A comparative study of ocular and generalized myasthenia gravis","author":"Hsu","year":"2002","journal-title":"Kaohsiung J Med Sci"},{"key":"key-10.4103\/2211-5056.213655-41","first-page":"687","volume-title":"EFNS\/ENS Guidelines for the treatment of ocular myasthenia","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"key":"key-10.4103\/2211-5056.213655-42","first-page":"1330","volume-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: Effects of treatment","author":"Kupersmith","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/2211-5056.213655-43","first-page":"131","volume-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"key-10.4103\/2211-5056.213655-44","first-page":"CD005081","volume-title":"Medical and surgical treatment for ocular myasthenia","author":"Benatar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/2211-5056.213655-45","first-page":"363","volume-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-46","first-page":"81","volume-title":"Gradually increasing doses of prednisone in myasthenia gravis.Reducing the hazards of treatment","author":"Seybold","year":"1974","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2211-5056.213655-47","first-page":"106","volume-title":"Myasthenia gravis: Pathogenesis and treatment","author":"Richman","year":"1994","journal-title":"Semin Neurol"},{"key":"key-10.4103\/2211-5056.213655-48","first-page":"243","volume-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"key-10.4103\/2211-5056.213655-49","first-page":"2144","volume-title":"Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-50","first-page":"379","volume-title":"Ocular myasthenia gravis in a senior population: Diagnosis, therapy, and prognosis","author":"Allen","year":"2010","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-51","first-page":"1778","volume-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis.Myasthenia Gravis Study Group","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-52","first-page":"449","volume-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","author":"Mantegazza","year":"1988","journal-title":"J Neurol"},{"key":"key-10.4103\/2211-5056.213655-53","first-page":"593","volume-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-54","first-page":"1438","volume-title":"Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-55","first-page":"400","volume-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-56","first-page":"394","volume-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","author":"Muscle","year":"2008","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-57","first-page":"719","volume-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2211-5056.213655-58","first-page":"539","volume-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/2211-5056.213655-59","first-page":"247","volume-title":"Cyclosporine in the treatment of myasthenia gravis","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"key-10.4103\/2211-5056.213655-60","first-page":"146","volume-title":"Efficacy of low-dose FK506 in the treatment of Myasthenia gravis \u2013 A randomized pilot study","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"key":"key-10.4103\/2211-5056.213655-61","first-page":"970","volume-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/2211-5056.213655-62","first-page":"344","volume-title":"Tacrolimus monotherapy: A promising option for ocular myasthenia gravis","author":"Yagi","year":"2013","journal-title":"Eur Neurol"},{"key":"key-10.4103\/2211-5056.213655-63","first-page":"97","volume-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"key-10.4103\/2211-5056.213655-64","first-page":"189","volume-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-65","first-page":"31","volume-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","author":"De","year":"2002","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/2211-5056.213655-66","first-page":"2390","volume-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","author":"Rowin","year":"2004","journal-title":"Neurology"},{"key":"key-10.4103\/2211-5056.213655-67","first-page":"181","volume-title":"The effectiveness of thymectomy on seronegative generalized myasthenia gravis: Comparing with seropositive cases","author":"Yuan","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"key-10.4103\/2211-5056.213655-68","first-page":"511","volume-title":"Randomized trial of thymectomy in myasthenia gravis","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2211-5056.213655-69","first-page":"332","volume-title":"Thymectomy in myasthenia with pure ocular symptoms","author":"Schumm","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/2211-5056.213655-70","first-page":"320","volume-title":"Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy","author":"Shrager","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"key-10.4103\/2211-5056.213655-71","first-page":"373","volume-title":"Therapeutic outcomes in thymectomied patients with myasthenia gravis","author":"Takanami","year":"2009","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"key-10.4103\/2211-5056.213655-72","first-page":"562","volume-title":"Thymectomy in the treatment of ocular myasthenia gravis","author":"Roberts","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key-10.4103\/2211-5056.213655-73","first-page":"1993","volume-title":"Extended transsternal thymectomy for the treatment of ocular myasthenia gravis","author":"Liu","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"key-10.4103\/2211-5056.213655-74","first-page":"1790","volume-title":"Ocular myasthenia gravis treatment: The case against prednisone therapy and thymectomy","author":"Gilbert","year":"2007","journal-title":"Arch Neurol"},{"key":"key-10.4103\/2211-5056.213655-75","first-page":"730","volume-title":"Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis","author":"Marulli","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key-10.4103\/2211-5056.213655-76","first-page":"173","volume-title":"Treatment of myasthenia gravis based on its immunopathogenesis","author":"Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"key-10.4103\/2211-5056.213655-77","first-page":"CD002277","volume-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/2211-5056.213655-78","first-page":"940","volume-title":"Changes in the lymphocyte subset after double-filtration plasmapheresis","author":"Yeh","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"key-10.4103\/2211-5056.213655-79","first-page":"1350","volume-title":"Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis","author":"Chien","year":"2011","journal-title":"Eur J Neurol"},{"key":"key-10.4103\/2211-5056.213655-80","first-page":"217","volume-title":"Prethymectomy plasmapheresis in myasthenia gravis","author":"Yeh","year":"2005","journal-title":"J Clin Apher"},{"key":"key-10.4103\/2211-5056.213655-81","first-page":"191","volume-title":"MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis","author":"Yeh","year":"2007","journal-title":"J Neurol Sci"},{"key":"key-10.4103\/2211-5056.213655-82","first-page":"751","volume-title":"Blepharoptosis in myasthenia gravis","author":"Castronuovo","year":"1983","journal-title":"Ann Ophthalmol"},{"key":"key-10.4103\/2211-5056.213655-83","first-page":"S55","volume-title":"Surgical correction of the intractable blepharoptosis in patients with ocular myasthenia gravis","author":"Lai","year":"2016","journal-title":"Ann Plast Surg"},{"key":"key-10.4103\/2211-5056.213655-84","first-page":"18","volume-title":"Active management in patients with ocular manifestations of myasthenia gravis","author":"Bentley","year":"2001","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/2211-5056.213655-85","unstructured":"Lee J. Management of selected forms of neurogenic strabismus. In: Rosenbaum A, Santiago A, editors. Clinical Strabismus Management: Principles and Surgical Techniques. Philadelphia: WB Saunders Company; 1999. p. 380-92."},{"key":"key-10.4103\/2211-5056.213655-86","first-page":"40","volume-title":"Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis","author":"Peragallo","year":"2013","journal-title":"J Neuroophthalmol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:40:00Z","timestamp":1786714800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_39_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"alternative-id":["213655"],"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo_39_17","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}